cancer showed reduced NK cell numbers and activity, with a high level of T-regulatory cells [7] . In hematological malignancies, de-
immune surveillance by various mechanisms, which induces reduced immunogenicity and leads to upregulation of inhibitory receptors on NK cells or downregulation of the ligands on tumor cells for NK cell activating receptors [1, 2] . Previously, increased expression of the inhibitory NKG2A receptor was observed in patients with renal cell carcinoma, resulting in decreased NK cell activity (NKA) [6] . Patients with prostate, gastrointestinal, or colon cancer showed reduced NK cell numbers and activity, with a high level of T-regulatory cells [7] . In hematological malignancies, de-
혈액종양 진단 시에 관찰되는 자연살해세포활성의 다양성
Variable Natural Killer Cell Activity in Hematological Malignancies at Diagnosis [8] [9] [10] .
NK cell infusion has been adopted to treat various malignancies as a form of cancer immunotherapy [11, 12] .
To measure the cytotoxicity of NK cells, the 51 Cr-release assay is considered the gold standard method. However, it is dangerous because of the radioactive hazard, and involves a complex method.
The expression of cell surface receptors and intracellular proteins associated with NKA or NK cell maturation can be measured by ow cytometry; however, ow cytometry is not a simple test for routine clinical testing.
Recently, a commercialized NKA assay kit (NK Vue assay, ATgen, Korea) was introduced. It is an easy to use quantitative sandwich enzyme-linked immunosorbent assay (ELISA) kit that can be used to measure interferon-gamma (IFN-γ) secreted by ex vivostimulated NK cells in whole blood [13, 14] .
The purpose of this study was to investigate the clinicopathological characteristics of NKA among various hematological malignancies at diagnosis and to evaluate their clinical value as a monitoring marker.
METHODS

Patients and samples
The study group included 111 patients diagnosed with hemato- To compare NKA in hematological malignancy with those in a normal control group, 23 healthy subjects were recruited from our health examination center out of 51 subjects who had the results of NKA for the same period. All the subjects had the results of complete blood cell (CBC) analysis. Thirteen patients with a history of hypertension, diabetes mellitus, and/or dyslipidemia were excluded. Five patients were excluded because of a history of thyroid cancer, two for autoimmune disease, two for glaucoma, four for recent medication, one for hepatitis B virus infection, and one for anemia.
Response criteria from the recommendations of the International Working Group for Response Criteria [15] were applied for AML. The International Myeloma Working Group uniform response criteria [16] and the revised response criteria from the International Working Group 1999 [17] were applied for MM and malignant lymphoma assessment, respectively.
NK cell activity measurement
Whole blood was collected in a tube containing PROMOCA, an engineered recombinant cytokine. The origin of IFN-γ secretion after PROMOCA stimulation in whole blood is as follows: CD3-/ CD56+ NK cells account for more than 50% of IFN-γ+ cells and CD3+ T cells and NKT cells for around 30% of IFN-γ+ cells [13] .
After 24 hours of incubation at 37°C in a CO2 chamber, the supernatant was collected and stored at −20°C until the IFN-γ secreted by the NK cells was measured using the ELISA method. All measurements were performed according to the manufacturer's instructions.
The normal reference interval was stated as ≥250 pg/mL by the manufacturer. The analytical measurement range (AMR) of the NK Vue kit is 40-2,000 pg/mL, as indicated by the manufacturer. Values outside of the AMR were regarded as extreme values: 40 pg/mL and 2,000 pg/mL.
Peripheral lymphocyte subset analysis
The peripheral lymphocyte subsets (CD3, CD4, CD8, CD19, and CD56/16) were investigated using monoclonal antibodies (BD Multitest 6-color TBNK, Becton Dickinson, San Jose, CA, USA) using 6-color ow cytometry analysis (FACSCanto II Flow Cytometer, Becton Dickinson). Peripheral blood NK cell numbers were determined using lymphocytes staining positive for CD56 and CD16, and negative for CD3. The reference intervals for NK cell percentage and number in our laboratory were 5-15% and 126-592/µL, respectively. Fig. 1 ) and the normal control group (P <0.0001). Signicantly lower NKA was observed in patients with MM (P <0.0001) and lymphoma (P <0.0001) compared with that in the controls.
Statistical analysis
Of the 57 patients with lymphoma who had bone marrow examination, the 11 patients with bone marrow involvement with lymphoma showed lower NKA (median 78.47 pg/mL, range 40-1,217. 20) compared with that in the 46 patients without bone marrow involvement (median 338.65 pg/mL, 40-2,000, P = 0.0566); however, the difference was not statistically signi cant.
The white blood cell (WBC) count in lymphoma was higher than that in the controls (P = 0.0160). The neutrophil count in AML was signi cantly lower than that in MM, lymphoma, and the controls (P = 0.0030, P = 0.0006, and P = 0.0135, respectively), while the neutrophil counts in MM and lymphoma were signi cantly higher than those in the controls (P = 0.0158 and P = 0.0008, respectively). Lymphocyte numbers in patents with AML were sig- 3. Serial NK cell activity during follow-up NKA was serially measured in 62 patients as a monitoring marker of immunological status during the follow-up period (from 2 to 27 months) (Fig. 2) In four patients (MM cases 3 Some patients showed consistently low or normal NKA levels, NKA is a well-conserved characteristic in an individual [19] . There have been reported defects in NKA in hematological malignancies [8] [9] [10] 20] ; however, it is not clear whether the decreased NKA in patients with hematological malignancies is the cause of cancer development or a result of it. The mechanisms of defective NKA could be quantitative (a decreased number of NK cells) or qualitative (increased expression of inhibitory receptors, decreased activation signaling, impaired NK cell differentiation signaling, or impaired cytokine production) [20] . A previous study revealed that a quantitative NK cell de ciency was found in myelodysplastic syndrome, whereas NKA was defective in polycythemia vera and chronic lymphocytic leukemia, even though the numbers of NK cells were increased [20] . Another study also reported qualitative defects of NKA in MM [10] . NK cell numbers were not changed or increased in MM; however, NKA decreased, as shown by altered patterns of activating and inhibitory receptors [10] . In patients with AML, a qualitative NKA defect was associated with reduced expression of certain activating NK receptors and decreased IFN-γ production [21] . In agreement with those studies, our study conrmed the qualitative impairment in NKA in hematological malignancies. As shown in Table 2 , there was no correlation between NKA and NK cell percentage and NK cell count. Therefore, to evaluate NK cells quantitatively and qualitatively, both NKA and NK cell number should be measured.
The median NKA for lymphoma in our study was 289.49 pg/mL and was higher compared with that in the AML group (Table 1) .
Lymphoma is a malignant neoplasm of B or T cells from the lymphatic system that provokes a host immune response. NK cell function can be in uenced primarily by the anatomical site of the tumor clone. One study showed that NK cell function is markedly impaired in patients with chronic lymphocytic leukemia (CLL), but is preserved in patients with small lymphocytic lymphoma (SLL) [22] . SLL is characterized by lymphadenopathy and/or sple- In non-Hodgkin's lymphoma (NHL) with unfavorable histology, NKA was decreased [23] . One study showed that NK cells showed activated phenotypes at early stages by reducing MHC class I expression of tumor cells; however, in later stages, tumor cells re express MHC class I and lose natural killer group 2D ligands (NKG2D-L), which results in a decreased NKA [24] . Thus, NK cell effector functions can be progressively exhausted by increasing tumor load at the later stages.
In this study, the serial changes in NKA correlated with the clinical course. NKA was stable during complete remission status, but decreased at the time of, or before, relapse and disease progression. NKA has been proposed as an immunological surrogate marker in patients with hematological malignancies and as a predictor of the effect of anticancer therapy [9, 10] . In AML, NK cytotoxicity and effector cytokine function were restored following induction chemotherapy [25] . AML patients with defective NK cells had a signi cantly higher risk of relapse [25] . MM patients showed a decreased NKA with advanced clinical stage, and patients with a high NKA after chemotherapy showed better survival than patients with a low NKA [26] . Interestingly, lenalidomide and pomalidomide for MM treatment stimulate NK cells [27] .
Some studies highlighted the ability of NK cells to exert potent anti-leukemic effects and to reduce relapse in patients after autologous or allogeneic SCT [2, 20, 28, 29] . In the present study, NKA of patients increased after SCT compared with that before SCT; these patients achieved complete remission. However, a decreased NKA was observed with relapse. One study showed that, during the rst few months post-SCT, NK cells were the predominant circulating lymphoid cell subset with the potential to control disease relapse [2] . Another study demonstrated that a low absolute NK cell count at 60 days post-transplant was independently associated with relapse and death among patients receiving reduced intensity conditioning, and there was no signi cant association between the absolute NK cell count and graft-versus-host disease [28] .
In conclusion, this study showed that NKA was signi cantly de- 
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